Bioactive peptides in cancer and inflammation: Mechanisms, model systems and clinical translation
- 1Department of Biological and Biomedical Sciences, College of Health and Life Sciences Hamad Bin Khalifa University Doha Qatar
- 2Biomedical Sciences Department, College of Health Sciences QU Health, Qatar University Doha Qatar
Abstract
Background Bioactive peptides (BAPs), derived from both natural and synthetic sources, are increasingly recognized as multifunctional agents with potential roles in the management of cancer and inflammatory conditions, in addition to their well‐established antimicrobial activity. Their biological activity is critically governed by their sequence‐dependent physicochemical properties, including charge hydrophobicity, amphipathicity, and well‐defined three‐dimensional conformation, such as α‐helices, β‐sheets, and coils, which collectively determine target specificity, membrane interaction, and intracellular activity, ultimately determining therapeutic effectiveness and safety. Method Aside from in vitro models, animal models further validated their efficacy, enabling mechanistic insights and high‐throughput screening. Result In cancer models, BAPs induce anti‐cancer activity through various mechanisms such as membrane disruption, mitochondrial dysfunction, ROS generation, apoptosis, inhibition of invasion, migration, and angiogenesis across multiple cancer types, including breast cancer, particularly triple‐negative breast cancer, colorectal, lung and melanoma, highlighting BAPs broad antitumor properties. Concurrently, BAPs regulate the immune system through cytokine modulation, NF‐κB signalling suppression, reduced immune cell infiltration and macrophage polarization promotion. Conclusion However, despite these advances, clinical translation remains limited due to poor stability, short half‐life, cytotoxicity, high production costs and optimized drug delivery systems. An integrated multidisciplinary approach with AI‐guided design places BAPs as promising precision medicine tools for specific, immunomodulatory, and personalized anticancer and anti‐inflammatory therapies.
Related
- In silico assessment of barnyard millet and blue pea derived bioactive peptides against Salmonella enterica Serovar Typhi and Clostridioides difficile
- Antimicrobial Peptides Against ESKAPE Pathogens: Mechanisms, Molecular Optimization, and Current Limitations
- Fungal melanin as a bioactive biopolymer: structural diversity, oxidative stress modulation, anticancer mechanisms, and therapeutic perspectives.
- Bee-Derived Products in Neurodegenerative Diseases: Bioactive Constituents, Redox-Modulating Mechanisms, Evidence, and Translational Perspectives
- Antibacterial and Anti-Inflammatory Activities of Moringa oleifera: Extracts, Bioactive Compounds, and Mechanisms.
BibTeX
@article{doha2026bioactive,
title = {{Bioactive peptides in cancer and inflammation: Mechanisms, model systems and clinical translation}},
author = {Najwa Doha and Richa Gill and Sergio Crovella and Haissam Abou‐Saleh and Sahar Isa Da'as},
journal = {Clinical and Translational Discovery},
year = {2026},
month = oct,
doi = {10.1002/ctd2.70209},
url = {https://doi.org/10.1002/ctd2.70209},
note = {CC BY},
}
RIS
TY - JOUR
TI - Bioactive peptides in cancer and inflammation: Mechanisms, model systems and clinical translation
AU - Najwa Doha
AU - Richa Gill
AU - Sergio Crovella
AU - Haissam Abou‐Saleh
AU - Sahar Isa Da'as
PY - 2026
DA - 2026/10/26
JO - Clinical and Translational Discovery
DO - 10.1002/ctd2.70209
UR - https://doi.org/10.1002/ctd2.70209
AB - Background Bioactive peptides (BAPs), derived from both natural and synthetic sources, are increasingly recognized as multifunctional agents with potential roles in the management of cancer and inflammatory conditions, in addition to their well‐established antimicrobial activity. Their biological activity is critically governed by their sequence‐dependent physicochemical properties, including charge hydrophobicity, amphipathicity, and well‐defined three‐dimensional conformation, such as α‐helices, β‐sheets, and coils, which collectively determine target specificity, membrane interaction, and intracellular activity, ultimately determining therapeutic effectiveness and safety. Method Aside from in vitro models, animal models further validated their efficacy, enabling mechanistic insights and high‐throughput screening. Result In cancer models, BAPs induce anti‐cancer activity through various mechanisms such as membrane disruption, mitochondrial dysfunction, ROS generation, apoptosis, inhibition of invasion, migration, and angiogenesis across multiple cancer types, including breast cancer, particularly triple‐negative breast cancer, colorectal, lung and melanoma, highlighting BAPs broad antitumor properties. Concurrently, BAPs regulate the immune system through cytokine modulation, NF‐κB signalling suppression, reduced immune cell infiltration and macrophage polarization promotion. Conclusion However, despite these advances, clinical translation remains limited due to poor stability, short half‐life, cytotoxicity, high production costs and optimized drug delivery systems. An integrated multidisciplinary approach with AI‐guided design places BAPs as promising precision medicine tools for specific, immunomodulatory, and personalized anticancer and anti‐inflammatory therapies.
SN - 2768-0622
ER -